Description
Diazepam
Diazepam is a benzodiazepine medicine used in oral tablet form. The verified active ingredient is diazepam, and the product is a 5 mg tablet. It is a central nervous system depressant with established uses in anxiety disorders, short-term relief of anxiety symptoms, and certain muscle-spasm or spasticity-related conditions. It is also used in some settings as an adjunct in seizure management.
Active Ingredient and Medicine Class
The active ingredient is diazepam. It belongs to the benzodiazepine class of medicines. Benzodiazepines are known for anxiolytic, sedative, muscle-relaxant, anticonvulsant, and amnestic effects. Diazepam is a controlled substance and carries risks of dependence, misuse, and withdrawal.
Established Medical Uses
Diazepam tablets are established for the management of anxiety disorders and for the short-term relief of symptoms of anxiety. Official prescribing information also supports use as an adjunct for relief of skeletal muscle spasm due to reflex spasm from local pathology or trauma, and for spasticity caused by upper motor neuron disorders such as cerebral palsy or paraplegia. Oral diazepam may also be used adjunctively in certain convulsive disorders, although it is not a sole therapy for those conditions.
The effectiveness of long-term use has not been established in systematic studies, so continued need is generally expected to be reassessed in clinical practice.
How It Works
Diazepam acts in the brain and spinal cord by enhancing the effect of gamma-aminobutyric acid, often called GABA, the main inhibitory neurotransmitter in the central nervous system. By strengthening this inhibitory signaling, diazepam reduces excessive neuronal activity, which helps explain its calming, muscle-relaxing, and anticonvulsant effects.
Important Safety Information
Diazepam should not be used in people with known hypersensitivity to diazepam. Official labeling also lists contraindications in myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, sleep apnea syndrome, and acute narrow-angle glaucoma. Caution is especially important in older adults and in people with liver disease or respiratory compromise, because accumulation and excessive sedation may occur.
Diazepam has clinically significant interactions with opioids and other central nervous system depressants, including alcohol, because combined use can increase the risk of profound sedation, respiratory depression, coma, and death. Drug interactions may also occur with agents that inhibit hepatic enzymes involved in diazepam metabolism, which can increase diazepam exposure. As with other benzodiazepines, diazepam can cause physical dependence, and abrupt discontinuation after continued use may trigger withdrawal reactions, including severe or life-threatening symptoms.
Possible Side Effects
Commonly recognised adverse effects include drowsiness, fatigue, dizziness, confusion, unsteadiness, slurred speech, and impaired coordination. Gastrointestinal symptoms such as nausea or constipation may also occur. Because diazepam can impair alertness and motor performance, sedation and slowed reactions are important practical concerns.
More serious adverse reactions may include respiratory depression, paradoxical agitation or disinhibition, severe allergic reactions, misuse and addiction, cognitive impairment, and withdrawal symptoms after dose reduction or stopping treatment. Severe overdose can cause coma and life-threatening breathing problems, especially when other sedatives are involved.
Scientific Evidence
Peer-reviewed literature supports diazepam’s established pharmacology as a benzodiazepine that enhances GABA-mediated inhibitory signaling and produces anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects. Clinical review literature also supports its use in anxiety disorders and selected spasticity or muscle-spasm settings. Human evidence and long-standing clinical experience are consistent with benefit in approved indications, while also showing important limitations related to sedation, tolerance, dependence, and withdrawal risk.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed. Diazepam Tablets, USP, CIV Rx only — prescribing information
- U.S. Food and Drug Administration. Valium (diazepam) tablets — official FDA label
- Dhaliwal JS et al. Diazepam. StatPearls, 2019. View scientific article
- Joshua M Lorenz-Guertin et al. Diazepam Accelerates GABAAR Synaptic Exchange and Alters Intracellular Trafficking. Frontiers in Cellular Neuroscience, 2019. View scientific article
- Wenyan Han et al. Shisa7 is a GABAA receptor auxiliary subunit controlling benzodiazepine actions. Science, 2019. View scientific article
